Market Overview

Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th

Related CYCC
Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering
Benzinga's Top #PreMarket Losers

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders announced today that updated Phase 3 clinical trial results for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) treated with sapacitabine and decitabine administered in alternating cycles will be presented at a poster presentation during the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, on Sunday, December 9, 2012.

The poster's abstract details are as follows:

Abstract: 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Title: Treated with Sapacitabine and Decitabine Administered in Alternating Cycles Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM Eastern Time   Hall B1-B2, Level 1, Building B (Georgia World Congress Center) Session: Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster II     Poster board: The abstract is available online at: https://ash.confex.com/ash/2012/webprogram/start.html.

Posted-In: News

 

Most Popular

Related Articles (CYCC + CYCCP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free